Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryJapanJapan
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

Defactinib hydrochloride

Defactinib hydrochloride
Contact us for more batch information
Select Batch
Resource Download

Defactinib hydrochloride

Catalog No. T15092Cas No. 1073160-26-5
Defactinib hydrochloride (PF 04554878 hydrochloride) is a novel inhibitor of FAK. Which inhibits FAK phosphorylation at the Tyr397 site in a time- and dose-dependent manner.
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
Pack SizePriceAvailabilityQuantity
2 mg$435 days
5 mg$676-8 weeks
Bulk & Custom
Add to Cart
View More

Related Compound Libraries of "Defactinib hydrochloride"

Product Introduction

Defactinib hydrochloride (PF 04554878 hydrochloride) is a novel inhibitor of FAK. Which inhibits FAK phosphorylation at the Tyr397 site in a time- and dose-dependent manner.
In vitro
Defactinib suppresses pFAK (protein Focal Adhesion Kinase) expression within three hours, exhibiting a dose-dependent inhibition, particularly at the Tyr397 phosphorylation site, and showing a reduction in expression levels by 48 hours. It effectively diminishes FAK phosphorylation over time and in correlation with the administered dose. Additionally, Reverse Phase Protein Array (RPPA) analysis reveals that Defactinib lowers AKT and YB-1 levels in taxane-resistant cell lines. The inhibition of pFAK (Tyr397) by Defactinib is confirmed to be statistically significant and dose-responsive across various cell lines, as documented in source [1].
In vivo
In the HeyA8 model, PTX monotherapy achieved an 87.4% decrease in tumor weight, while combination therapy yielded a superior 97.9% reduction (P=0.05 compared with PTX). Defactinib treatment at 25 mg/kg, administered orally twice daily, significantly decreased pFAK (Tyr397) levels, with effects reversing within 24 hours, establishing this dose for further experiments. For these, female nude mice with HeyA8 tumors in the peritoneal cavity were divided into four groups (n=10 each): 1) control group receiving vehicle and phosphate-buffered saline, 2) Defactinib (25 mg/kg orally, twice daily), 3) PTX weekly, and 4) both Defactinib and PTX. The SKOV3ip1 model demonstrated a 92.7% tumor weight reduction with the combination therapy compared to PTX alone (P<0.001)[1].
AliasVS-6063 hydrochloride, PF 04554878 hydrochloride
Chemical Properties
Molecular Weight546.95
Cas No.1073160-26-5
Storage & Solubility Information
Storage Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Solubility Information
DMSO: 22.5 mg/mL (41.1 mM)
H2O: 0.1 mg/mL (insoluble)
Solution Preparation Table
50 mM0.0366 mL0.1828 mL0.3657 mL1.8283 mL
100 mM0.0183 mL0.0914 mL0.1828 mL0.9142 mL


  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
1 Enter information below:
2 Enter the in vivo formulation:
%Tween 80

Dose Conversion

You can also refer to dose conversion for different animals. More

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc